It can inhibit the growth and proliferation of Helicobacter pylori, and significantly reduce the adhesion of H. pylori to cells such as SGC7901SGC7901 (human gastric cancer cells), GES1GES1 (human gastric epithelial cells), AGSAGS (human gastric cancer cells), and MKN45MKN45 (human gastric cancer cells), creating conditions for the eradication of Helicobacter pylori, and Lp05 will not produce drug resistance and will not cause adverse reactions in patients during treatment.

It can inhibit the growth and proliferation of various Helicobacter pylori subtypes, inhibit the adhesion of Helicobacter pylori to gastric epithelial cells, and significantly reduce the colonization and inflammatory response of different subtypes of Helicobacter pylori, creating a basis for the eradication of Helicobacter pylori conditions.

Population trials have shown that LRa09 effectively reduces the levels of inflammatory factors in patients with Helicobacter pylori infection and significantly reduces the adhesion of Helicobacter pylori to gastric epithelial cells. At the same time, LRa09 has a strong inhibitory effect on pathogenic bacteria such as Streptococcus mutans, Streptococcus cousinis, Streptococcus sanguinis, Proteus, Helicobacter pylori, Bacteroides fragilis, Listeria monocytogenes and other pathogenic bacteria.

It can effectively inhibit Helicobacter pylori infection and significantly inhibit the adhesion of Helicobacter pylori to AGS cells and SGC7901 cells. Population trials have shown that BBr96 will not produce drug resistance or cause adverse reactions in patients when used for anti-plasmic treatment, and is safe and effective.